{'fraction_non_alphanumeric': 0.036290322580645164, 'fraction_numerical': 0.016129032258064516, 'mean_word_length': 5.626666666666667, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Inhibition of the renal renin‐angiotensin system and renoprotection by pitavastatin in type 1 diabetes

1. The aim of the present study was to investigate whether or not pitavastatin ameliorates diabetic nephropathy and if inhibition of the rennin–angiotensin–aldosterone system (RAAS) is associated with any renoprotective effects. Pitavastatin (10 mg/ kg/day) and/or spironolactone (100 mg/kg/day) were given by gavage for 3 weeks to uninephrectomized rats with streptozotocin‐induced diabetes.